761299AB2

Retrophin Inc

Could not find a ticker for this position, may be a filing error

A biopharmaceutical company that develops and sells medicines for rare kidney, liver, and metabolic diseases, including the kidney drug FILSPARI and the legacy products Thiola and Thiola EC. It was founded in 2011 by Martin Shkreli, who coined the name "Retrophin" as a mash-up of "replace dystrophin," reflecting its original goal of treating Duchenne muscular dystrophy. In 2020 the company rebranded as Travere Therapeutics to shed its association with its founder.

2.5% Convertible Senior Notes due September 15, 2025

No filing summaries or text available for this security.